Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Home
Esther Hulleman

Esther Hulleman

Principal Investigator

Hulleman group

Phone 088 97 252 14

Email E.Hulleman@prinsesmaximacentrum.nl

Gemcitabine therapeutically disrupts essential SIRT1-mediated p53 repression in atypical teratoid/rhabdoid tumors
- sep. 2024
- Dennis S, Metselaar, et al
- Cell Reports Medicine
The heterogeneous sensitivity of pediatric brain tumors to different oncolytic viruses is predicted by unique gene expression profiles
- apr. 2024
- Konstantinos, Vazaios, et al
- Molecular therapy. Oncology
A road map for the treatment of pediatric diffuse midline glioma
- nov. 2023
- , et al
- Cancer Cell
Microglia in pediatric brain tumors
- nov. 2023
- Aimée, du Chatinier, et al
- Cell Reports Medicine
Tocilizumab for the fifth progression of cystic childhood craniopharyngioma-a case report
- okt. 2023
- Evelien, de Vos-Kerkhof, et al
- Frontiers in endocrinology

View all publications

Esther Hulleman

Publications

Gemcitabine therapeutically disrupts essential SIRT1-mediated p53 repression in atypical teratoid/rhabdoid tumors

The heterogeneous sensitivity of pediatric brain tumors to different oncolytic viruses is predicted by unique gene expression profiles

A road map for the treatment of pediatric diffuse midline glioma

Microglia in pediatric brain tumors

Tocilizumab for the fifth progression of cystic childhood craniopharyngioma-a case report